Head-to-head evidence
CJC-1134-PC vs elecoglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
CJC-1134-PC
Developed by ConjuChem
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
elecoglipron
Developed by AstraZeneca
NCT06579105 · Phase 2 · completed
Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.
Next expected readout: May 2028 · NCT07664553 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CJC-1134-PC's landscape · elecoglipron's landscape